Name : Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein
Product Source :
Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein is expressed from E.coli with with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGADGVGK peptide.[Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGADGVGK]
Molecular Weight :
The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer is greater than 95% as determined by SEC-HPLC.
Background :
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms :
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
References & Citations :
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CD204/MSR1 Protein
VEGF165 Protein
Popular categories:
DEP-1 Proteins
FcRn